Non Small Cell Lung Cancer
Conditions
Keywords
I131, L19, antibody, monoclonal, NSCLC, lung, tumor targeting, radioimmunotherapy, Patients with newly diagnosed inoperable, locally-advanced (stage III) NSCLC
Brief summary
The aim of this feasibility study is to determine the therapeutic potential of the L19SIP antibody, labeled with the radionuclide 131I in combination with radiochemotherapy, for the treatment of patients with newly diagnosed, unresectable, locally-advanced NSCLC following the promising results with this agent in previous clinical studies. The L19SIP antibody is a fully human antibody, capable of preferential localization around tumor blood vessels while sparing normal tissues. The formation of new blood vessels is a rare event in the adult (with the exception of the female reproductive tract), but it is a characteristic pathological feature for most types of aggressive cancer.
Interventions
OTHER131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy
Lung tumor irradiation with a total dosage of between 60-66 Gy, fractionated in combination with the following concurrent chemotherapy options: 1. Cohorts 1, 2 & 3a is composed of cisplatin i.v. 80 mg/m2 on day 1, and vinorelbine i.v. 25 mg/m2 on day 1, 8, 15 for cycle 1 & 4. For patients with significant comorbidities, the dose of vinorelbine is reduced to 12.5 mg/m2 during cycles 2 & 3. Treatment cycles will be repeated every 28 days. 2. Protocol A (suggested for patients with comorbidities: Carboplatin 70 mg/m2, over 30 min iv, (Day 1-5 ) + Vinorelbine 12.5 mg/m2 as a 5-min bolus iv or short iv-infusion (Day 1, 8, 22), repeated on Day 28. 3. Protocol B (suggested for patients in good clinical condition): Paclitaxel 50 mg/m2 1 hour iv (Day 1, 15, 22, 29, 36, 43, 50) + Carboplatin AUC 2, 30 min iv on (Day 1, 15, 22, 29, 36, 43, 50). * Total treatment duration is 8-16 weeks
Sponsors
Philogen S.p.A.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed unresectable stage III NSCLC * Males or females, age ≥ 18 years * Measurable lung lesion defined as at least one lesion that can be accurately and serially measured per the modified RECIST criteria. * ECOG performance status \< 3 * Life expectancy of at least 12 weeks * Patients eligible for concurrent radiochemotherapy (cisplatin/vinorelbine; 60-66 Gy EBRT) at the discretion of the clinical investigator * Absolute neutrophil count \> 1.5 x 109/L, hemoglobin \> 9.0 g/dL and platelets \> 100 x 109/L * Total bilirubin ≤ 30 µmol/L (or ≤ 2.0 mg/Dl) * ALT and AST ≤ 2.5 x the upper limit of normal (5.0 x ULN for patients with hepatic involvement with tumor * Serum creatinine \< 1.5 x ULN * All toxic effects of prior therapy must have resolved to ≤ Grade 1 unless otherwise specified above * Negative serum pregnancy test (for women of child-bearing potential only) at screening
Exclusion criteria
* Patients with metastatic disease * Patients amenable for surgical resection of lung tumor lesions * Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (TA, Tis & Ti) or any cancer curatively treated \< 5 years prior to study entry * History of HIV infection or infectious hepatitis B or C * Presence of active infections (e.g. requiring antibimicrobial therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study. * Inadequately controlled cardiac arrhythmias including atrial fibrillation * Heart insufficiency (\> Grade II, New York Heart Association (NYHA) criteria) * Uncontrolled hypertension * Ischemic peripheral vascular disease (Grade IIb-IV) * History of an acute cardiac event such as myocardial infarction, instable angina pectoris during the last 12 months * Severe diabetic retinopathy * Active autoimmune disease * History of organ allograft or stem cell transplantation * Recovery from major trauma including surgery within 4 weeks prior to administration of study treatment * Breast feeding female * Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before administration of study treatment * Growth factors or immunomodulatory agents within 7 days of the administration of study treatment (131I-L19SIP application). * Hyperthyroidism or autonomous thyroid nodule
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Uptake of 131I-L19SIP or 124I-L19SIP | 2 days | The selective uptake of 131I-L19SIP or 124I-L19SIP in lung lesions and dosimetric analysis |
| Safety and tolerability of 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy | 13 months | Safety will be assessed through physical examinations, vital signs, laboratory tests (including serum chemistries, hematology parameters) and the recording of adverse events. All results from these assessments will be coded using CTCAE v.3 and presented descriptively, indicating frequency and percentage of patients with adverse events, and abnormal laboratory tests. These results will be presented by related/unrelated and overall for the study. |
| Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose/Recommended Dose (MTD/RD) for the combination treatment | 4 weeks | Dose limiting toxicities and maximum tolerated dose/recommended dose for the combination treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate | 1 year | Intrapulmonal, extra pulmonal and overall response rate |
| Overall survival | 1 year | — |
Countries
Italy
Outcome results
None listed